bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version contact us  confluence pharmaceuticals confluence pharmaceuticals home about us pipeline news contact us for more information or to contact us name  first last email  comment  submit confluence pharmaceuticals llc west th streetbox indianapolis in    create a free website powered by ✕ confluence pharmaceuticals  home confluence pharmaceuticals home about us pipeline news contact us restoring hope unlocking potential confluences mission is to advance all research in autism and fragile x syndrome and bring to market a solution that treats core social and communication impairments  we understand the profound impact of being able to communicate and socially interact has on everyday life  we want to change the way people think about treating fragile x and autismand how they will administer or direct therapies in the future what we do confluence is developing a novel clinicallydiscovered therapeutic treatment for core social and communication impairments caused by fragile x syndrome and autism spectrum disorders we are targeting important functionality  talking thinking social interaction and selfcare  create a free website powered by ✕ confluence pharmaceuticals  home confluence pharmaceuticals home about us pipeline news contact us restoring hope unlocking potential confluences mission is to advance all research in autism and fragile x syndrome and bring to market a solution that treats core social and communication impairments  we understand the profound impact of being able to communicate and socially interact has on everyday life  we want to change the way people think about treating fragile x and autismand how they will administer or direct therapies in the future what we do confluence is developing a novel clinicallydiscovered therapeutic treatment for core social and communication impairments caused by fragile x syndrome and autism spectrum disorders we are targeting important functionality  talking thinking social interaction and selfcare  create a free website powered by ✕ news  confluence pharmaceuticals confluence pharmaceuticals home about us pipeline news contact us in the news confluence pharmaceuticals signs codevelopment and marketing agreement with aop orphan pharmaceuticals for fragile x drugpress releaseconfluence receives european orphan drug designation for fragile x syndromehttpeceuropaeuhealthdocumentscommunityregisterhtmlorphreghtmnational fragile x research foundation recognizes dr craig erickson for outstanding research and clinical service to worldwide fragile x communityhttpwwwfragilexorginternationalfragilexconferenceconferenceawardconfluence receives us orphan drug designation for fragile x syndromehttpwwwaccessdatafdagovscriptsopdlistingoopdoopdresultscfmindexnumber3943the john merck fund awards dr erickson  million research grant acamprosate for fxshttpwwwfragilexorg3foundationpressreleasemerckfundautism speaks funds dr ericksons research  acamprosate for asd with trailblazer awardhttpwwwautismspeaksorgsciencegrantsacamprosateyouthautismspectrumdisordersvideo  standards for diagnosing autism under review nbc news interviewhttptodaymsnbcmsncomid649vp47774777 bioscience technology  fragile x gene’s prevalence suggests broader health riskhttpwwwbiosciencetechnologycomnewsvideo  study shows  in  have autism  fox news interview with dr craig ericksonhttpwwwfoxcomvideogallery6937newsvideostudyshowsinhaveautismindianapolis star interview   rising star dr craig ericksonhttpwwwindystarcomarticle7business47risingstardrcraigericksonautismspecialistdr craig erickson discusses the drug acamprosate for the treatment of fragile xhttpnfxfblogspotcomdrcraigericksondiscussesdrughtmlarticle  video   indy doctors treat autism with alcoholism drughttpwwwtheindychannelcomnews76796detailhtmlncb affiliate wthr3   new study uses alcoholism treatment for fragile xhttpwwwwthrcomstory436796newstudyusesalcoholismtreatmentforfragilexclient create a free website powered by ✕ about us  confluence pharmaceuticals confluence pharmaceuticals home about us pipeline news contact us management team confluence has assembled an experienced management team business and science advisory boards and attracted various other important collaborators to our effort  the management teams experience spans from the launch of new businesses through capitalization commercialization and exit steven l johns president and founder  steve johns has built a reputation as a visionary innovator and leader through a variety of diverse experiences acquired in a number of successful startups and early stage companies his work career includes  years in banking  financial management and 5 years in his own business ventures steve’s business experience extends in these key areas strategic planning building management teams transforming business models mergers  acquisitions and capital formation  mr johns holds a bs degree from the university of illinois and an mba from indiana university  he currently sits on the board of the venture club of indiana dr craig a erickson lead scientific advisor  founder dr erickson is the chief of the fragile x research and treatment center at cincinnati childrens hospital medical center adjunct assistant professor of psychiatry at indiana university school of medicine former chief of the christian sarkine autism treatment center and former chief of fragile x research and treatment center riley hospital for children indiana university school of medicine  he is currently directing several research projects with patients being treated at indiana university and is involved with other national fragile x syndrome and autism spectrum disorder related research boyd w sturdevant jr chairman and founder boyd sturdevant jr has been associated with the mental health industry most of his  year career   he developed and recently sold indiana’s largest freestanding employee assistance business and pioneered percapita mental health managed care programs with employers  boyd brings a depth of working knowledge in the areas of commercializing mental health services engaging mental health advocateconsumer groups measuring perception of treatment outcomes and executives coaching and consultation  he has served on his national professional board and chaired the state of indiana mental health advisory council  he has a bs from indiana university and master of ministry from christian theological seminary timothy f parshall vice president of corporate affairs mr parshall has over 5 years experience in global healthcare strategy marketing and business development  mr parshall has been a director of strategic marketing at both guidant and eli lilly  company  he led product marketing and technology acquisition efforts on a national and international level   his current focus is on the development of startup and earlystage revenue companies in both the medical device and biotechnology fields  mr parshall is the founder of pivotal strategies—a strategic marketing and business development organization based in indianapolis in   he has a bachelors degree in pharmacy from the university of sydney and a master of business administration from the university of new south wales australia  dr sharon rosenzweiglipson vice president of research dr rosenzweiglipson has over  years experience developing compounds for psychiatric and neurologic indications in the pharmaceutical industry american cyanamid – american home products – wyeth – pfizer sharon has successfully led teams from the earliest exploratory studies through to phase ii proof of concept trials in  she founded ivs pharma consulting llc to bring her expertise in in screening strategies in vivo models translation and early clinical development strategy to the neuroscience scientific community in pharma biotech and academia kenneth g payie phd rac director of cmc dr ken payie has almost a decade in the large pharma industry in a variety of research and development positions  with a background in large and small molecule chemistry manufacturing  controls cmc development virtual drug development experience and six sigma black belt execution dr payie has developed a number of large and small molecule cmc programs in the candidate identification to phase ii space for both large pharma and small drug discovery companies  dr payie has designed and directed drug development programs through outsourcing to asia europe and north american vendors and dramatically reduced costs to develop assets without compromising quality in  dr payie founded kgpbiotech consulting llc to bring his expertise to the scientific and drug development communities   in addition to his involvement with kgp and confluence dr payie has held senior positions at chorus europe vanthys pharmaceutical development and eli lilly business  scientific advisory boards represented in alphabetical order by last name leonard abbeduto phd  sab emeritus dr abbeduto is professor of educational psychology communicative disorders and psychology and a director of the internationally recognized mind institute at university of california davis campus  he is the former associate director for behavioral sciences and director of the university center for excellence in developmental disabilities at the university of wisconsins waisman center he is considered one of the leading scholars investigating the language problems of children with intellectual disabilities including fragile x syndrome down syndrome autism language disorders and family impacts of these developmental disabilities  he has published over  articles chapters and reviews as well as seven books his research has been supported by the nih almost continuously since 94  among his many notable achievements abbeduto has received the charles j anderson professor of education in  the uwmadison kellett midcareer research award in  the uwmadison school of education distinguished faculty achievement award in  the emil a steiger distinguished teaching award in 996 and is a fellow american association on intellectual and developmental disabilities and is a past chair of the department of educational psychology he is the presidentelect of the academy on mental retardation and the codirector of the nihfunded gatlinburg conference on intellectual and developmental disabilities  dr abbeduto earned his phd in psychology from the university of illinois at chicago in 9 he completed a postdoctoral fellowship at vanderbilt university before joining the faculty at the university of wisconsinmadison in 97 michael aman phd  sab dr michael aman is a professor of psychology and psychiatry at ohio state university where he directs one of eight nimh research units on pediatric psychopharmacology dr aman was a codeveloper of the aberrant behavior checklist abc and of the nisonger child behavior rating form ncbrf the abc has been used extensively in pharmacological and other research in people with autism spectrum disorders and other developmental disabilities to date there are over 75 studies with the abc and it has been translated into at least 6 foreign languages dr aman has over  scholarly publications including two editions of the popular text practitioners guide to psychoactive drugs for children and adolescents  dr aman is on the editorial boards of seven scientific journals in 3 dr aman received a career scientist award from the american academy on mental retardation bradley w fravel phd  bab sabdr fravel is a business development manager at the indiana university research  technology corporation brad’s responsibilities include technology evaluation marketing intellectual property strategy  management and technology commercialization   having held positions as an academic and an industry scientist he understands the benefits of strong relationships between faculty researchers and the private sector  prior to joining the iurtc brad taught chemistry at butler university and worked with the butler business accelerator  brad came to butler after spending two years in washington dc evaluating large national and international capital projects as an analyst for the consulting firm independent project analysis  prior to ipa brad was a research chemist and project manager for indianapolisbased reilly industries a global specialty chemicals company an indiana native brad earned a phd in organic chemistry from indiana university after graduating with a bachelor of science degree in chemistry from southern methodist university in dallas tx  he also has an mba in finance from butler university bryan h king md sab dr king is professor and vice chair of psychiatry and behavioral sciences and director of child and adolescent psychiatry at the university of washington and seattle children’s hospital dr king’s clinical and research interests have been focused on psychiatric aspects of developmental disorders repetitive movements and upon the pathogenesis and treatment of behavioral disturbance in autism he currently chairs a multisite psychopharmacology network for the national institutes of health funded staart studies to advance autism research and treatment centers formed to examine the potential role for an antidepressant medication in the treatment of children with autism who have significant problems with repetitive behaviors he is also director of the nih funded uw autism center of excellence and the seattle children’s autism center  dr king completed his medical training at the medical college of wisconsin and subsequently did his medical internship and psychiatric training at the ucla medical center and neuropsychiatric institute he obtained his clinical and research training in child and adolescent psychiatry at ucla and at the merck neuroscience research center in england with sponsorship of the national institutes of health  dr king is a coauthor on the practice parameters for children and adults with developmental disorders and mental illnesses by the american academy of child and adolescent psychiatry he has written extensively in the medical literature relating to this field and has received lifetime achievement awards from the american academy of child and adolescent psychiatry and from the american psychiatric association for his work in the field of developmental disabilities joseph muldoon  bab chief executive officer  board director fast biomedical mr muldoon leverages decades of experience from technology startups to publiclytraded multinationals he has worked with dozens of entrepreneurial companies with roles spanning advisor investor and ceo as an entrepreneur in residence of the indiana venture center  his focus is enterprise value creation culture building and mergers acquisitions and exits  his medical technology experience includes tgx medical vascalert dynomed sold to chartlogic trust bearer labs sold to verisign and geist pharmaceuticals  previously he was president and ceo of firstmile technologies a startup broadband provider he led through its sale  prior to that he served as president of brightpoint north america a publicly traded fortune  wireless company that grew fourfold to mm under his leadership he has also held executive management positions at macmillan  he started his career as a cpa in ernst  young’s entrepreneurial services practice  mr muldoon has a bachelor of science in business from indiana university’s kelley school of business where he is a panelist and speaker for multiple mba programs legal regulatory and other collaborators   confluence has retained the services of the following professionals to assist in the company’s legal regulatory and other affairs mr marcus b chandler  martin zivitz legal advisorsattorneyatlawbarnes  thornburg llp south meridian streetindianapolis in  464 mr kenneth v phelps regulatory advisorpresident  ceocamargo pharmaceutical services llc95 kenwood road  suite 3cincinnati oh  454 mr david nelson phd neuropharmacology discovery  developmentfounder council mountain pharma consultingphoenix az create a free website powered by ✕ pipeline  confluence pharmaceuticals confluence pharmaceuticals home about us pipeline news contact us drug development pipeline the pharmacological dynamics of our therapeutic agents match the heterogeneity of these disorders which is in sharp contrast to other drugs that target a single neurochemical mechanism or pathway  create a free website powered by ✕ about us  confluence pharmaceuticals confluence pharmaceuticals home about us pipeline news contact us management team confluence has assembled an experienced management team business and science advisory boards and attracted various other important collaborators to our effort  the management teams experience spans from the launch of new businesses through capitalization commercialization and exit steven l johns president and founder  steve johns has built a reputation as a visionary innovator and leader through a variety of diverse experiences acquired in a number of successful startups and early stage companies his work career includes  years in banking  financial management and 5 years in his own business ventures steve’s business experience extends in these key areas strategic planning building management teams transforming business models mergers  acquisitions and capital formation  mr johns holds a bs degree from the university of illinois and an mba from indiana university  he currently sits on the board of the venture club of indiana dr craig a erickson lead scientific advisor  founder dr erickson is the chief of the fragile x research and treatment center at cincinnati childrens hospital medical center adjunct assistant professor of psychiatry at indiana university school of medicine former chief of the christian sarkine autism treatment center and former chief of fragile x research and treatment center riley hospital for children indiana university school of medicine  he is currently directing several research projects with patients being treated at indiana university and is involved with other national fragile x syndrome and autism spectrum disorder related research boyd w sturdevant jr chairman and founder boyd sturdevant jr has been associated with the mental health industry most of his  year career   he developed and recently sold indiana’s largest freestanding employee assistance business and pioneered percapita mental health managed care programs with employers  boyd brings a depth of working knowledge in the areas of commercializing mental health services engaging mental health advocateconsumer groups measuring perception of treatment outcomes and executives coaching and consultation  he has served on his national professional board and chaired the state of indiana mental health advisory council  he has a bs from indiana university and master of ministry from christian theological seminary timothy f parshall vice president of corporate affairs mr parshall has over 5 years experience in global healthcare strategy marketing and business development  mr parshall has been a director of strategic marketing at both guidant and eli lilly  company  he led product marketing and technology acquisition efforts on a national and international level   his current focus is on the development of startup and earlystage revenue companies in both the medical device and biotechnology fields  mr parshall is the founder of pivotal strategies—a strategic marketing and business development organization based in indianapolis in   he has a bachelors degree in pharmacy from the university of sydney and a master of business administration from the university of new south wales australia  dr sharon rosenzweiglipson vice president of research dr rosenzweiglipson has over  years experience developing compounds for psychiatric and neurologic indications in the pharmaceutical industry american cyanamid – american home products – wyeth – pfizer sharon has successfully led teams from the earliest exploratory studies through to phase ii proof of concept trials in  she founded ivs pharma consulting llc to bring her expertise in in screening strategies in vivo models translation and early clinical development strategy to the neuroscience scientific community in pharma biotech and academia kenneth g payie phd rac director of cmc dr ken payie has almost a decade in the large pharma industry in a variety of research and development positions  with a background in large and small molecule chemistry manufacturing  controls cmc development virtual drug development experience and six sigma black belt execution dr payie has developed a number of large and small molecule cmc programs in the candidate identification to phase ii space for both large pharma and small drug discovery companies  dr payie has designed and directed drug development programs through outsourcing to asia europe and north american vendors and dramatically reduced costs to develop assets without compromising quality in  dr payie founded kgpbiotech consulting llc to bring his expertise to the scientific and drug development communities   in addition to his involvement with kgp and confluence dr payie has held senior positions at chorus europe vanthys pharmaceutical development and eli lilly business  scientific advisory boards represented in alphabetical order by last name leonard abbeduto phd  sab emeritus dr abbeduto is professor of educational psychology communicative disorders and psychology and a director of the internationally recognized mind institute at university of california davis campus  he is the former associate director for behavioral sciences and director of the university center for excellence in developmental disabilities at the university of wisconsins waisman center he is considered one of the leading scholars investigating the language problems of children with intellectual disabilities including fragile x syndrome down syndrome autism language disorders and family impacts of these developmental disabilities  he has published over  articles chapters and reviews as well as seven books his research has been supported by the nih almost continuously since 94  among his many notable achievements abbeduto has received the charles j anderson professor of education in  the uwmadison kellett midcareer research award in  the uwmadison school of education distinguished faculty achievement award in  the emil a steiger distinguished teaching award in 996 and is a fellow american association on intellectual and developmental disabilities and is a past chair of the department of educational psychology he is the presidentelect of the academy on mental retardation and the codirector of the nihfunded gatlinburg conference on intellectual and developmental disabilities  dr abbeduto earned his phd in psychology from the university of illinois at chicago in 9 he completed a postdoctoral fellowship at vanderbilt university before joining the faculty at the university of wisconsinmadison in 97 michael aman phd  sab dr michael aman is a professor of psychology and psychiatry at ohio state university where he directs one of eight nimh research units on pediatric psychopharmacology dr aman was a codeveloper of the aberrant behavior checklist abc and of the nisonger child behavior rating form ncbrf the abc has been used extensively in pharmacological and other research in people with autism spectrum disorders and other developmental disabilities to date there are over 75 studies with the abc and it has been translated into at least 6 foreign languages dr aman has over  scholarly publications including two editions of the popular text practitioners guide to psychoactive drugs for children and adolescents  dr aman is on the editorial boards of seven scientific journals in 3 dr aman received a career scientist award from the american academy on mental retardation bradley w fravel phd  bab sabdr fravel is a business development manager at the indiana university research  technology corporation brad’s responsibilities include technology evaluation marketing intellectual property strategy  management and technology commercialization   having held positions as an academic and an industry scientist he understands the benefits of strong relationships between faculty researchers and the private sector  prior to joining the iurtc brad taught chemistry at butler university and worked with the butler business accelerator  brad came to butler after spending two years in washington dc evaluating large national and international capital projects as an analyst for the consulting firm independent project analysis  prior to ipa brad was a research chemist and project manager for indianapolisbased reilly industries a global specialty chemicals company an indiana native brad earned a phd in organic chemistry from indiana university after graduating with a bachelor of science degree in chemistry from southern methodist university in dallas tx  he also has an mba in finance from butler university bryan h king md sab dr king is professor and vice chair of psychiatry and behavioral sciences and director of child and adolescent psychiatry at the university of washington and seattle children’s hospital dr king’s clinical and research interests have been focused on psychiatric aspects of developmental disorders repetitive movements and upon the pathogenesis and treatment of behavioral disturbance in autism he currently chairs a multisite psychopharmacology network for the national institutes of health funded staart studies to advance autism research and treatment centers formed to examine the potential role for an antidepressant medication in the treatment of children with autism who have significant problems with repetitive behaviors he is also director of the nih funded uw autism center of excellence and the seattle children’s autism center  dr king completed his medical training at the medical college of wisconsin and subsequently did his medical internship and psychiatric training at the ucla medical center and neuropsychiatric institute he obtained his clinical and research training in child and adolescent psychiatry at ucla and at the merck neuroscience research center in england with sponsorship of the national institutes of health  dr king is a coauthor on the practice parameters for children and adults with developmental disorders and mental illnesses by the american academy of child and adolescent psychiatry he has written extensively in the medical literature relating to this field and has received lifetime achievement awards from the american academy of child and adolescent psychiatry and from the american psychiatric association for his work in the field of developmental disabilities joseph muldoon  bab chief executive officer  board director fast biomedical mr muldoon leverages decades of experience from technology startups to publiclytraded multinationals he has worked with dozens of entrepreneurial companies with roles spanning advisor investor and ceo as an entrepreneur in residence of the indiana venture center  his focus is enterprise value creation culture building and mergers acquisitions and exits  his medical technology experience includes tgx medical vascalert dynomed sold to chartlogic trust bearer labs sold to verisign and geist pharmaceuticals  previously he was president and ceo of firstmile technologies a startup broadband provider he led through its sale  prior to that he served as president of brightpoint north america a publicly traded fortune  wireless company that grew fourfold to mm under his leadership he has also held executive management positions at macmillan  he started his career as a cpa in ernst  young’s entrepreneurial services practice  mr muldoon has a bachelor of science in business from indiana university’s kelley school of business where he is a panelist and speaker for multiple mba programs legal regulatory and other collaborators   confluence has retained the services of the following professionals to assist in the company’s legal regulatory and other affairs mr marcus b chandler  martin zivitz legal advisorsattorneyatlawbarnes  thornburg llp south meridian streetindianapolis in  464 mr kenneth v phelps regulatory advisorpresident  ceocamargo pharmaceutical services llc95 kenwood road  suite 3cincinnati oh  454 mr david nelson phd neuropharmacology discovery  developmentfounder council mountain pharma consultingphoenix az create a free website powered by ✕   microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext7 about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext775 where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext776 personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext77 personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext779 personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext7 legal privacy  cookies   microsoft confluence pharmaceuticals llc in indianapolis in   w th st ste  indianapolis in  back to previousconfluence pharmaceuticals llcfreein business since more lesswebsiteview menu more detailsthe person icon employee image indicates that the reviewer is an employee of dex media inc dex media operates and sells advertising on superpagescom the views expressed in reviews are the opinion of each respective reviewer and do not necessarily reflect the view of dex mediadata provided by one or more of the following dex media acxiom infogroup yext pingup confluence pharmaceuticals llc  carmel  in  company information products resources my account talk to a db advisor 7 business directory in carmel drugs proprietaries and sundries pharmaceuticals confluence pharmaceuticals llc c confluence pharmaceuticals llc claim this business 494 deer ridge dr s carmel in 4633 get directions   business info founded  incorporated in annual revenue 549 employee count  industries pharmaceuticals contacts boyd w sturdevant jr contact business your email address subject message send message company summary confluence pharmaceuticals llc is located at 494 deer ridge dr s in carmel and has been in the business of pharmaceuticals since  verified status unverified address unverified last verified  phone unverified payment method unverified view full report similar businesses nearby our similar businesses nearby shows similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile competitive landscape our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile payments accepted no data hours sunday   monday   tuesday   wednesday   thursday   friday   saturday   c view additional data select from over 5 networks below to view available data about this business if this data is unavailable or inaccurate and you own or represent this business click here for more information on how you may be able to correct it credibility review google facebookcom yellowbookcom bingcom yellowpagescom merchantcircle tele atlas tomtom twittercom aol mapquest yahoo local applesiri groupon hotfrogcom comcastnet search reachlocal admedia dealsplus shoptopiacom alteryx dogtime media kslcom sirtune americantownscom driverside kudzucom specialsagentcom answerscom egood lawinfocom spotlikescom anywhocom egumball likenesscom spotzot eservicelog mapmyrun technocom apartmentguidecom ezlocalcom eztousecom teleroute aroundmecom metropolistcom therapistscom atlanta newhomes findlawcom time out new york avantar findthebestcom mojopagescom bb yellowpages fivestar software mycitywaycom tripadvisor bckyrdcom giftcardscom mycouponscom beachcaliforniacom golocal47com mymovecom upmesocialcom belo goodinfo newsgazette nokia usdirectorycom carscom nomao centzycom hibu openlistcom chacha search homeplatecom ownlocalcom visikard challamacom homestore patchcom voltari citybot pelopidas vouchd classifiedads hostway placeiq walkscorecom cloudmade hoodoyou planetdiscovercom weddingwirecom powerprofiles where inc contractorscom igolocalcom radiate media wikiocity couponmap indeedcom wimgocom crowdspot innova electronics intellistrand realtorcom datasphere inthemocom replycom yellowbotcom jiwire rocket fuel yellowpagecitycom dmvorg justclicklocalcom dirxion keencom zidstercom photos business credit report receive a onetime comprehensive credit report on this company get full credit report facebook twitter yelp call 7 to speak with a db advisor today customer resources products education center business articles  insights glossary contact us customer support communication preferences search for db duns our company about us company history business credit history careers press releases news success stories hoovers our network partners affiliates blog access to capital entrepreneurial initiative db international supplieredge site links business directory site map pipeda privacy policy website terms of service product license agreement  dun  bradstreet inc  all rights reserved   bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one confluence pharmaceuticals llc company profile  bloomberg feedback confluence pharmaceuticals llc private company company profile sector health care industry health care facilities  svcs subindustry health care services confluence pharmaceuticals llc provides health care services the company offers clinicallydiscovered therapeutic treatment for social and communication impairments caused by fragile x syndrome and autism spectrum disorders confluence pharmaceuticals serves patients in the united states corporate information address  west th street box  indianapolis in  united states phone  fax  web url wwwconfluencepharmacom from the web sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data confluence pharmaceuticals  angellist join   log in angellist startup jobs recruit invest more companies freelancers incubators track salaries valuations help your alumni network companies freelancers incubators track salaries valuations help   confluence pharmaceuticals is on angellist where the world meets startups to connect with confluence pharmaceuticals sign up for angellist today sign up log in confluence pharmaceuticals novel patented autism  fragile x drug discovery share indianapolis neuroscience · therapeutics · biotechnology · life sciences employees confluencepharmacom sign up to see how you are connected to confluence pharmaceuticals confluence pharmaceuticals share company overview overview there was a problem loading your content product confluence pharmaceuticals is the exclusive licensee of aclinically discovered novel therapeutic treatment for core social and communication impairments in individuals suffering from autism spectrum disorders asd and fragile x syndrome fxs there is no fda approved medication for these lifelong impairments according to published studies the potential success of a therapeutic drug could… · more reduce the cost of lifelong care by as much as twothirds founders steve johns cofounder of confluencepharmaceuticals former ceo of egix inc former ceo of ens inc former managing member of dsl indiana acquisitions llc boyd w sturdevant jr chairman and founder of confluence pharmaceuticals llc craig erickson founder  lead scientific advisor md psychiatry chief christian sarkine autism center and fragile x research  treatment center iu school of medicine funding investors from previous rounds steve johns unmet need market orphan drug candidate has significant human data in disease states boyd w sturdevant jr chairman and founder of confluence pharmaceuticals llc craig erickson founder  lead scientific advisor md psychiatry chief christian sarkine autism center and fragile x research  treatment center iu school of medicine team advisors tim parshall director at pivotal strategies llc and biotechnology consultant joe muldoon board member at confluence pharmaceuticals llc bradley fravel business development manager at the indiana university research  technology corporation phd chemistry mba finance jobs confluence pharmaceuticals hasnt added any jobs yet notification set get notified which position are you applying for add a message to confluence pharmaceuticals apply notify me when confluence pharmaceuticals lists jobs create notification see similar jobs view jobs page people also viewed imstar therapeutics transforming als  neurodegenerative verge genomics faster cures using genomics yc s5 neurogenica systems biology and genomics let us halo neuroscience neurosciencebased technology for optempus medical better surgical tools cerora device  software platform for brain cambridge bioaugmentation systems plug  play bionic devices enterowave minimally invasive neurostimulators help · directory · blog twitter · terms  risks · unsubscribe · mobile · desktop · profile not verified